Abrégé

This method for predicting the effectiveness of dupilumab administration to an atopic dermatitis patient comprises a step for measuring the concentration of at least one biomarker in a blood sample derived from the patient before dupilumab administration, wherein: the concentration of the biomarker is an indicator for predicting the effectiveness of the dupilumab administration; and the biomarker is selected from the group consisting of interleukin (IL)-22, C-C Motif Chemokine Ligand (CCL) 20, IL-18, IL-17, Tumor Necrosis Factor (TNF)-α, and C-X-C Motif Chemokine 9 (CXCL9).

Classes IPC  ?

• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
• C12N 15/115 - Aptamères, c.-à-d. acides nucléiques liant spécifiquement une molécule cible avec une haute affinité sans s'y hybrider

Abrégé

A polishing tool for polishing a workpiece by holding a polishing material between the workpiece and its polishing surface, the polishing tool including: a main shaft part that has the polishing surface at a front end and that extends along a polishing axis; a plurality of elastic parts that are continuous from the main shaft part and that extend radially outward; and a plurality of seat parts that are continuous to the radially outside of the plurality of elastic parts. A position at which the main shaft part connects to each of the elastic parts and a position at which the corresponding seat part connects thereto are different in a direction of the polishing axis.

Classes IPC  ?

• B24B 37/005 - Moyens de commande pour machines ou dispositifs de rodage

Abrégé

Provided is a method for predicting the efficacy of dupilumab administration to an atopic dermatitis patient, the method comprising a step for measuring the expression level of at least one biomarker in a skin tissue sample from the patient prior to dupilumab administration, wherein the expression level of the biomarker is an indicator for predicting the efficacy of dupilumab administration.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• C12Q 1/6813 - Tests d’hybridation
• C12Q 1/6876 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

Provided is a system for controlling a flow of a fluid in a microfluidic device, the system comprising: a microfluidic device comprising a microfluidic housing portion for housing fluid; a photo-rheological fluid housed in the microfluidic housing portion; a first light source for irradiating the photo-rheological fluid with a first light beam; and a second light source for irradiating the photo-rheological fluid with a second light beam having a wavelength different from that of the first light beam. The first light source is configured to irradiate the photo-rheological fluid in the microfluidic housing portion with the first light beam, and the second light source is configured to irradiate a portion of the photo-rheological fluid in a region irradiated with the first light beam, with the second light beam.

Classes IPC  ?

• B01J 19/00 - Procédés chimiques, physiques ou physico-chimiques en généralAppareils appropriés
• B01J 19/12 - Procédés utilisant l'application directe de l'énergie ondulatoire ou électrique, ou un rayonnement particulaireAppareils à cet usage utilisant des radiations électromagnétiques
• B81B 1/00 - Dispositifs sans éléments mobiles ou flexibles, p. ex. dispositifs capillaires microscopiques
• G01N 1/00 - ÉchantillonnagePréparation des éprouvettes pour la recherche
• G01N 37/00 - Détails non couverts par les autres groupes de la présente sous-classe

Abrégé

The present invention addresses the problem of providing a method for detecting a bacterium-derived molecule contained in blood, which can be a diagnostic marker or a subject for basic research. The problem is solved by analyzing a sample prepared from a blood specimen and detecting a bacterium-derived low-molecular-weight RNA.

Classes IPC  ?

• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
• A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
• A61P 35/00 - Agents anticancéreux
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
• C12Q 1/6806 - Préparation d’acides nucléiques pour analyse, p. ex. pour test de réaction en chaîne par polymérase [PCR]
• C12Q 1/6816 - Tests d’hybridation caractérisés par les moyens de détection
• C12Q 1/6869 - Méthodes de séquençage
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet

Abrégé

A temperature imaging device that can visualize a temperature change by color even with a large area. The temperature imaging device includes: a base material; and a composite having polyallylamine introduced between layers of poly-10,12-pentacosadiynoic acid, the composite being incorporated into the base material or caused to adhere onto the base material.

Classes IPC  ?

• G01N 25/00 - Recherche ou analyse des matériaux par l'utilisation de moyens thermiques
• A61B 5/01 - Mesure de la température de parties du corps
• A61B 18/00 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci
• A61B 18/14 - Sondes ou électrodes à cet effet

Abrégé

An electronic display device (1) for a vehicle comprises: an imaging section (2) for capturing an image at least to the rear of a vehicle; a control unit (4) for acquiring the image captured by the imaging section 2, and changing a luminance histogram included in the information of the image to execute image processing for generating a display image having a diopter value smaller than that of the image captured by the imaging section (2); and a display section (5) for displaying the display image generated by the control unit (4).

Classes IPC  ?

• H04N 7/18 - Systèmes de télévision en circuit fermé [CCTV], c.-à-d. systèmes dans lesquels le signal vidéo n'est pas diffusé
• H04N 13/128 - Ajustement de la profondeur ou de la disparité

Abrégé

The present invention addresses the problem of providing a method for determining a person showing responsiveness to bleach therapy.　The present invention encompasses a method for determining responsiveness to bleach therapy, the method involving a determination step a in which, when a bacterium contained in a subject sample has one or more selected from the base sequences described in SEQ ID NO:1 to SEQ ID NO:173 and base sequences showing 80% or greater identity with said base sequences, it is determined that the subject shows responsiveness to bleach therapy.

Classes IPC  ?

• C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
• C12Q 1/686 - Réaction en chaine par polymérase [PCR]

Abrégé

An object of the present invention is to provide, for example, a therapeutic agent for hepatic disorders using a specific mesenchymal stem cell line derived from an adipose tissue (ASCL), the therapeutic agent being capable of being preserved and stably supplied and having a better therapeutic effect on hepatic disorders. A feature of the present invention is to use a mesenchymal stem cell line derived from an adipose tissue, the mesenchymal stem cell line having been produced by a production method comprising: (A) inducing differentiation of one or more cells selected from a stromal vascular fraction of a vertebrate animal adipose tissue comprising a mesenchymal stem cell, an adipose progenitor cell, and a stromal cell into a mature adipocyte; and (B) inducing dedifferentiation of the mature adipocyte obtained in step (A) to obtain a mesenchymal cell line derived from the vertebrate animal adipose tissue.

Classes IPC  ?

• A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
• A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
• C12N 5/0775 - Cellules souches mésenchymateusesCellules souches dérivées du tissu adipeux

Abrégé

This eyepiece optical device is characterized by comprising: an eyepiece member that comes into contact with a cornea; a recess that is formed on the cornea-side surface of the eyepiece member and is recessed in a spherical shape; and a light source unit that is positioned outside of the recess and that irradiates the aqueous humor inside the cornea with light. Provided as a result is an eyepiece optical device with which it is possible to suppress variations in the amount of light emitted to the aqueous humor.

Classes IPC  ?

• A61B 3/117 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour examiner la chambre antérieure ou l'angle de la chambre antérieure, p. ex. gonioscopes
• A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
• G01N 21/64 - FluorescencePhosphorescence

Abrégé

This catheter embolization training method includes: a step for using a substrate 20 having a first opening part 22, a second opening part 23, and a passage 24 extending between the first opening part 22 and the second opening part 23, and administering, into the passage 24, a liquid 14 containing a polymer having a nucleophilic group so as to flow from the first opening part 22 to the second opening part 23 through the passage 24; and a step for administering a liquid 42 containing a cyanoacrylate-based adhesive from the first opening part 22 of the substrate 20.

Classes IPC  ?

• G09B 23/28 - Modèles à usage scientifique, médical ou mathématique, p. ex. dispositif en vraie grandeur pour la démonstration pour la médecine
• G09B 19/00 - Enseignement non couvert par d'autres groupes principaux de la présente sous-classe

Abrégé

Provided are: a culture medium which is for producing an organoid and which comprises a prostaglandin, hepatocyte growth factor (HGF), an interleukin (IL)-6 family protein, and an epidermal growth factor (EGF) family protein; a kit for cultivating an organoid; a method for producing an organoid; and an organoid.

Classes IPC  ?

• C12N 5/02 - Propagation de cellules individuelles ou de cellules en suspensionLeur conservationMilieux de culture à cet effet
• C12N 5/09 - Cellules tumorales
• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• C12N 5/095 - Cellules souchesCellules progénitrices
• C12N 5/0775 - Cellules souches mésenchymateusesCellules souches dérivées du tissu adipeux

Abrégé

Provided are: a method for producing an organoid, the method comprising a step for culturing somatic stem cells in a culture medium containing an agonist of the interferon-γ receptor; and a culture medium for producing an organoid, the culture medium containing an agonist of the interferon-γ receptor.

Classes IPC  ?

• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• C12N 5/074 - Cellules souches adultes

Abrégé

A learning apparatus acquires teaching data including input data. The input data includes an input image and an input text. The input image includes a reference object. The input text relatively designates a target position with reference to the reference object. The apparatus generates output data by inputting the input data to a model. The output data is for specifying the target position. The model includes first and second submodels. The first submodel generates, based on the input image and the input text, a plurality of feature amounts representing the reference object. The plurality of feature amounts have different resolutions from each other. The second submodel generates the output data based on the plurality of feature amounts and the input text. Each of the plurality of feature amounts is input to the second submodel.

Classes IPC  ?

• G06T 7/70 - Détermination de la position ou de l'orientation des objets ou des caméras

Abrégé

A moving object control system in the present disclosure performs to acquire an image, acquire a user instruction in a natural language including a relative positional relationship; and predict a region in the image corresponding to a position in a scene indicated by the user instruction based on a fused feature obtained by fusing an image feature indicating a feature of the scene captured in the image, a depth of the scene captured in the image, and a language feature indicating a linguistic feature related to the user instruction by using one or more machine learning models.

Classes IPC  ?

• G06V 10/25 - Détermination d’une région d’intérêt [ROI] ou d’un volume d’intérêt [VOI]
• G06T 7/50 - Récupération de la profondeur ou de la forme
• G06V 10/44 - Extraction de caractéristiques locales par analyse des parties du motif, p. ex. par détection d’arêtes, de contours, de boucles, d’angles, de barres ou d’intersectionsAnalyse de connectivité, p. ex. de composantes connectées
• G06V 10/80 - Fusion, c.-à-d. combinaison des données de diverses sources au niveau du capteur, du prétraitement, de l’extraction des caractéristiques ou de la classification

Abrégé

The present invention is a transmitter that is provided with: an optical comb signal generation unit that generates a first optical comb signal and has a plurality of emission lines arrayed at equal intervals in a frequency range; a modulation unit that modulates the first optical comb signal using a delivery signal to output a second optical comb signal; and a frequency shift unit that is provided with a photonic filter unit that performs filtering so as to impose a prescribed time delay between the emission lines that are adjacent in the second optical comb signal to output a third optical comb signal and a photoelectric conversion unit that, in the third optical comb signal, converts beat signals between the emission lines that are adjacent in the second optical comb signal into electrical signals.

Classes IPC  ?

• H04B 10/50 - Émetteurs
• G02F 1/01 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p. ex. commutation, ouverture de porte ou modulationOptique non linéaire pour la commande de l'intensité, de la phase, de la polarisation ou de la couleur

Abrégé

The present invention addresses the problem of providing a composition, preparation, pharmaceutical composition, or food containing a bacterial strain capable of inducing beige cells in mammals including humans, and a method for inducing beige cells by administering the bacterial strain. In order to solve the above problem, the present invention provides the following. A composition comprising a bacterium having a DNA sequence having at least 90% identity with the sequence of SEQ ID NO: 3, a bacterium having a DNA sequence having at least 90% identity with the sequence of SEQ ID NO: 4, a bacterium having a DNA sequence having at least 90% identity with the sequence of SEQ ID NO: 14, and a bacterium having a DNA sequence having at least 90% identity with the sequence of SEQ ID NO: 30.

Classes IPC  ?

• A61K 35/74 - Bactéries
• A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
• A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
• A61K 47/04 - Non-métauxLeurs composés
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 47/28 - Stéroïdes, p. ex. cholestérol, acides biliaires ou acide glycyrrhétinique
• A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
• A61P 3/04 - AnorexigènesMédicaments de l'obésité
• A61P 3/06 - Antihyperlipémiants
• A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
• C12N 1/20 - BactériesLeurs milieux de culture

Abrégé

The present invention relates to a transcranial magnetic stimulation system and a transcranial magnetic stimulation method. This transcranial magnetic stimulation system comprises: a control device that performs magnetic generation control on a magnetism generation device and performs action control on a robot, these controls being performed in parallel; and a force sensor that is provided at the distal end of an arm part or between the distal end and a coil unit 30. Each time the control device brings the coil unit into contact with a head through action control performed on the robot, the control device performs calibration of the force sensor prior to contact.

Classes IPC  ?

• A61N 2/04 - Magnétothérapie utilisant des champs magnétiques produits par des bobines, y compris par des boucles à spire unique ou par des électro-aimants utilisant des champs variables, p. ex. des champs basse fréquence ou des champs pulsés

Abrégé

An infrared microscope including a light source that emits infrared light of which intensity increases and decreases repetitively, a collecting element that collects the infrared light from the light source, an irradiating side objective element that irradiates the sample with infrared light, a collecting side objective element that collects the infrared light transmitted through the sample, a spectroscopic portion that spectrally processes the collected infrared light, a detector of the infrared light; and a signal processing portion that performs lock-in detection to a detection signal by using a reference signal that synchronizes with an intensity of the infrared light to acquire an infrared spectrum of the sample. The light source has a light-emitting surface having a size of 0.1 μm or greater and 20 μm or less. Light-emitting surface's image is formed on the sample by the collecting element and the irradiating side objective element.

Classes IPC  ?

• G01N 21/35 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge
• G01N 21/55 - Réflexion spéculaire
• G01N 21/59 - Transmissivité

Abrégé

A medical instrument with little risk of clot formation even when blood is flowed therethrough, said medical instrument (1) comprising a plurality of blood channel layers (3), wherein the plurality of blood channel layers (3) each have a plate-shaped main body (5), a groove (9) for forming a blood channel (7), and a resin layer (11) formed on the side wall of the groove (9). A manufacturing method of the medical instrument comprises: a resin applying step for applying a resin to the groove (9) of the plate-shaped main body (5) having the groove (9) for forming the blood channel (7); a bonding step for sandwiching the plate-shaped main body (5) between a first film (41) and a second film (43) and thus bonding the plate-shaped main body (5), the first film (41) and the second film (43); and a post-curing step for, after the bonding step, curing the resin applied to the groove (9) in the resin applying step.

Classes IPC  ?

• A61M 1/34 - Filtration du sang à travers une membrane pour en éliminer une matière, c.-à-d. hémofiltration, diafiltration
• A61M 1/14 - Systèmes de dialyseReins artificielsOxygénateurs du sang

Abrégé

The present invention provides a prophylactic or therapeutic composition for graft-versus-host disease (GVHD). There is provided a prophylactic or therapeutic composition for GVHD, which comprises bacteria belonging to any genus selected from the group consisting of the following genera: Blautia, Clostridium, unclassified Clostridiales, Actinomyces, Parabacteroides, Lachnoclostridium, Bacteroides, Faecalibacterium, unclassified Lachnospiraceae, Roseburia, Ruminococcus, unclassified Firmicutes, Dorea, Phascolarctobacterium, Sutterella, Megamonas, Collinsella, Eubacterium, and Coprococcus, etc., or any combination of bacteria belonging to these genera.

Classes IPC  ?

• A61K 35/74 - Bactéries
• A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
• A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe

Abrégé

Provided are: an agent for organoid formation and proliferation in the absence of an extracellular matrix, the agent including a Hippo signaling pathway inhibitor as an active component; a method for organoid proliferation; an organoid proliferated by the above-described proliferation method; an agent for establishing an organoid in the absence of an extracellular matrix; a method for producing an organoid; an organoid produced by the above-described production method; a regenerative medicine preparation; and a method for screening for an agent that enables culture of an organoid in the absence of an extracellular matrix.

Classes IPC  ?

• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• A61K 35/38 - EstomacIntestinCellules caliciformesMuqueuse oraleSalive

Abrégé

Provided are a connection device in which flow stagnation does not readily occur, and a method for manufacturing the same. This connection device (1) has an internal cavity (9) for connecting, in a state allowing fluid transport, a flow path (3) and a housing (7) accommodating membranes (5), the connection device (1) also having a plurality of flow path adjustment walls (13) provided in the internal cavity (9). The method for manufacturing the connection device (1) includes a step for installing, in a main body section (11) of the connection device (1), a plurality of virtual flow path layers having thicknesses corresponding to inter-membrane flow paths (17) formed by a plurality of stacked membranes (5), a step for forming the plurality of flow path adjustment walls (13) among the plurality of virtual flow path layers, and a step for obtaining inter-adjustment-wall flow paths (15) formed by the plurality of flow path adjustment walls (13) by forming the plurality of flow path adjustment walls (13) and then removing the virtual flow path layers.

Classes IPC  ?

• A61M 39/10 - Raccords ou accouplements pour tubes

Abrégé

Provided is a means to create an animal model that reproduces a state in which an abnormality has occurred in the ocular fundus due to elongation of the eye axis.　An animal model creation method according to the present invention includes a step for inducing myopia in an animal and raising the animal for a specific period of time. The specific period of time is at least 1.5 times the period of time from the induction of myopia to a plateau in reduction of refractive power.

Classes IPC  ?

• A01K 67/027 - Nouvelles races ou races modifiées de vertébrés
• G01N 33/15 - Préparations médicinales
• G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

An information processing apparatus acquires an image as input information and uses one or more machine learning models to extract a feature from the input information and to predict a specific region in the image based on the extracted feature. The information processing apparatus outputs a prediction result indicating the specific region including coordinates of a plurality of points surrounding the specific region and information indicating a next point after each of the plurality of points, and trains the one or more machine learning models using a loss function based on a difference between the prediction result including the coordinates of the plurality of points surrounding the specific region and information indicating the next point after each of the plurality of points and ground truth data for the prediction result.

Classes IPC  ?

• G06V 10/44 - Extraction de caractéristiques locales par analyse des parties du motif, p. ex. par détection d’arêtes, de contours, de boucles, d’angles, de barres ou d’intersectionsAnalyse de connectivité, p. ex. de composantes connectées
• G06V 10/25 - Détermination d’une région d’intérêt [ROI] ou d’un volume d’intérêt [VOI]
• G06V 10/80 - Fusion, c.-à-d. combinaison des données de diverses sources au niveau du capteur, du prétraitement, de l’extraction des caractéristiques ou de la classification

Abrégé

A medium for culturing a pluripotent stem cell, a pluripotent stem cell culture preparation, and a method for culturing a pluripotent stem cell, and a medium additive for promoting proliferation of a pluripotent stem cell. The medium includes L-tryptophan or a dipeptide in which L-tryptophan and an amino acid are peptide-bonded at a concentration of not less than 176 μM. The dipeptide may include L-alanyl-L-tryptophan.

Classes IPC  ?

• C12N 5/074 - Cellules souches adultes

Abrégé

An eyepiece optical lens includes: a base that has a plurality of faces; a concave portion that forms one face of the base, and is concave in a spherical shape; and a reflection portion that forms a face on an outer peripheral side of the concave portion of the base, the reflection portion reflecting, toward the concave portion, light that has been made incident on the base from a face that is included in the plurality of faces and is different from the concave portion. This provides an eyepiece optical lens that enables a non-invasive analysis of substances contained in aqueous humor of a subject eye.

Classes IPC  ?

• A61B 3/117 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour examiner la chambre antérieure ou l'angle de la chambre antérieure, p. ex. gonioscopes
• A61B 3/14 - Dispositions spécialement adaptées à la photographie de l'œil

Abrégé

In the present invention, smooth muscle production molds for forming a main blood vessel part and a branched blood vessel part are prepared. For the main blood vessel part, a smooth muscle layer is formed on a first core rod that has at least one hole, and for the branched blood vessel part, a smooth muscle layer is formed on a surface of a second core rod that has a diameter which enables fitting to the hole of the first core rod. Thereafter, the second core rod having the smooth muscle layer is fitted to the hole of the first core rod, thereby bringing the two smooth muscle layers into contact to form a branched structure, and thus a branched artificial blood vessel model is manufactured. The present invention makes it possible to provide a branched artificial blood vessel model which has a branched blood vessel shape and which constricts and relaxes according to physiological conditions.

Classes IPC  ?

• A61L 27/50 - Matériaux caractérisés par leur fonction ou leurs propriétés physiques
• A61F 2/06 - Vaisseaux sanguins
• A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
• A61L 27/40 - Matériaux composites, c.-à-d. en couches ou contenant un matériau dispersé dans une matrice constituée d'un matériau analogue ou différent
• A61L 27/44 - Matériaux composites, c.-à-d. en couches ou contenant un matériau dispersé dans une matrice constituée d'un matériau analogue ou différent comportant une matrice macromoléculaire
• G09B 23/28 - Modèles à usage scientifique, médical ou mathématique, p. ex. dispositif en vraie grandeur pour la démonstration pour la médecine

Abrégé

The purpose of the present invention is to provide a new marker that indicates the relevance between a vaccine and the immunity of a subject inoculated with the vaccine. More specifically, the purpose of the present invention is to provide, for example, a method for determining the waning of vaccine effect using a new marker correlated with a tendency of vaccine effect to wane. The problem is solved by providing a method for determining the waning of vaccine effect, the method comprising a step for detecting a mutation in an immunoglobulin heavy-chain region in DNA contained in a sample from a subject, wherein, when the mutation is detected in the immunoglobulin heavy-chain region, the vaccine effect in the subject is determined to have a high tendency to wane.

Classes IPC  ?

• C12Q 1/6827 - Tests d’hybridation pour la détection de mutation ou de polymorphisme
• C12Q 1/686 - Réaction en chaine par polymérase [PCR]
• C12Q 1/6872 - Méthodes de séquençage faisant intervenir la spectrométrie de masse
• C12Q 1/6874 - Méthodes de séquençage faisant intervenir des réseaux d’acides nucléiques, p. ex. séquençage par hybridation [SBH]
• C12Q 1/6876 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes

Abrégé

An antibacterial composition against drug-resistant bacteria or pro-inflammatory bacteria is disclosed. The antibacterial composition contains an intestinal bacterium as an active ingredient. Also uses of such composition useful for treating, ameliorating, or preventing an infectious disease or an inflammatory disease, and a pharmaceutical composition containing an intestinal bacterium as an active ingredient are disclosed.

Classes IPC  ?

• A61K 35/741 - Probiotiques
• A61K 35/00 - Préparations médicinales contenant des substances ou leurs produits de réaction de constitution non déterminée
• A61P 31/04 - Agents antibactériens

Abrégé

To provide a device for monitoring a blood flow at the time when the blood flow is stopped using an aortic blockage balloon to thereby prevent complete blockage of the blood flow and prevent outbreak of complications. A balloon catheter device comprising: a balloon catheter including a catheter tube and an aortic blockage balloon provided at a distal end portion of the catheter tube; one or more optical fibers housed in the catheter tube; one or more light irradiation devices disposed in the balloon and coupled to the optical fibers and one or more light detection parts that detect backscattered light of radiated light; and one or more light sources that generate light to be radiated, wherein the balloon catheter device radiates, from the aortic blockage balloon into an aorta, light having a wavelength that can be absorbed by a substance present in blood, detects backscattered light from an inside of a blood vessel, and monitors a state of a blood flow between the aortic blockage balloon and a blood vessel wall over time from intensity of the detected light.

Classes IPC  ?

• A61M 25/10 - Cathéters à ballon
• A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux
• A61B 17/12 - Instruments, dispositifs ou procédés chirurgicaux pour ligaturer ou comprimer par un autre moyen les parties tubulaires du corps, p. ex. les vaisseaux sanguins ou le cordon ombilical

Abrégé

The present invention is to provide a means for enhancing skeletal muscle. According to the present invention, the skeletal muscle is enhanced by using spermidine or a pharmaceutically acceptable salt thereof is administered intramuscularly as an active ingredient.

Classes IPC  ?

• A61K 31/132 - Amines, p. ex. amantadine ayant plusieurs groupes amino, p. ex. spermidine, putrescine
• A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire

Abrégé

An optical repeater comprising: a synthesizing/branching device that branches downlink signal light outputted from a base station into individual downlink signal light outputted to each of a plurality of user terminals, and that synthesizes individual uplink signal light outputted from each of the plurality of user terminals and outputs the synthesized uplink signal light to the base station as uplink signal light; a first optical fiber that transmits power supply light outputted from the base station; and an optical amplification circuit that amplifies any of the uplink signal light, the individual downlink signal light, and the individual uplink signal light by power obtained by photoelectrically converting the power supply light.

Classes IPC  ?

• H04B 10/291 - Répéteurs dans lesquels le traitement ou l’amplification est effectuée sans conversion de la forme optique du signal
• H04B 10/80 - Aspects optiques concernant l’utilisation de la transmission optique pour des applications spécifiques non prévues dans les groupes , p. ex. alimentation par faisceau optique ou transmission optique dans l’eau
• H04B 10/272 - Réseaux du type étoile
• H04J 14/02 - Systèmes multiplex à division de longueur d'onde

Abrégé

The present invention provides a method for inducing the differentiation of pluripotent stem cells into dopaminergic neural cells or a method for producing a cell group containing dopaminergic neural cells from pluripotent stem cells, each of the methods comprising: (1) bringing the pluripotent stem cells into contact with a TGFβ inhibitor, a BMP inhibitor, and/or a GSK3β inhibitor; and (2) expressing Ascl1 gene in the pluripotent stem cells.

Classes IPC  ?

• C12N 5/0793 - Neurones
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• C12N 15/12 - Gènes codant pour des protéines animales

Abrégé

This pharmaceutical composition is for treating or preventing anti-neutrophil cytoplasmic antibody-associated vasculitis, and contains an anti-IL-33 antibody as an active ingredient. The pharmaceutical composition according to another embodiment is for reducing the need for surgery in endometriosis patients or adenomyosis uteri patients, and contains an IL-33 antagonist as an active ingredient. The pharmaceutical composition according to another embodiment is for treating or preventing endometriosis or adenomyosis uteri, contains an anti-IL-33 antibody as an active ingredient, is administered once every 2 to 8 weeks, and is administered so that the blood trough level of the anti-IL-33 antibody is 6.7 μg/mL or more.

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons

Abrégé

The present invention relates to a pharmaceutical composition for preventing/treating an ocular complication in cGVHD, the composition containing, as an active ingredient, (R)-6-(2-methyl-1,4-diazocan-1-ylsulfonyl)isoquinoline represented by formula (1) or an acid addition salt thereof, or a solvate of the compound or the acid addition salt.

Classes IPC  ?

• A61K 31/4725 - Isoquinoléines non condensées, p. ex. papavérine contenant d'autres hétérocycles
• A61P 27/02 - Agents ophtalmiques
• A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe

Abrégé

Provided is a silk fibroin tubular substance used for reproducing a biological tissue. The silk fibroin tubular substance exhibits a porous makeup at room temperature, the patency rate of the silk fibroin tubular substance when a 1N load is applied thereon in a water-saturated state being 10%-50%.

Classes IPC  ?

• A61L 27/22 - Polypeptides ou leurs dérivés
• A61L 27/50 - Matériaux caractérisés par leur fonction ou leurs propriétés physiques
• A61L 27/56 - Matériaux poreux ou cellulaires
• C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains

Abrégé

What is provided is a therapeutic agent that is effective for the treatment of ovarian clear cell carcinoma. A therapeutic agent for ovarian clear cell carcinoma includes, as an active ingredient, a proteasome inhibitor. Furthermore, in the therapeutic agent for ovarian clear cell carcinoma, the proteasome inhibitor is a substance that reversibly or irreversibly binds to a 20s proteasome-β5 subunit and inhibits a chymotrypsin-like activity. Moreover, in the therapeutic agent for ovarian clear cell carcinoma, the proteasome is a 26s proteasome. In addition, in the therapeutic agent for ovarian clear cell carcinoma, a content proportion of the proteasome inhibitor is 80% by mass or more, 90% by mass or more, or 100% by mass.

Classes IPC  ?

• A61K 31/69 - Composés du bore
• A61K 38/07 - Tétrapeptides
• A61P 35/00 - Agents anticancéreux

Abrégé

Provided are a simple and highly accurate sample test method, which is capable of being applied to an evaluation of the presence or absence of one or more selected from the group consisting of a gynecological cancer and a precancerous lesion thereof, an evaluation of prognosis of a gynecological cancer patient, or an evaluation of a degree of malignancy of the gynecological cancer, a test kit capable of being used for the test method, and a medicine for treating or preventing a gynecological cancer, which is to be administered to a subject detected by the test method.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• G01N 33/92 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des lipides, p. ex. le cholestérol

Abrégé

What is provided is a production method for an organoid, including dissociating a biological tissue and carrying out suspension culture of the dissociated biological tissue in a state of being dispersed in a medium to form an organoid, in which the medium is substantially free of a p38 inhibitor and contains the following components (i) to (iv): (i) 0.1% to 10% by volume of an extracellular matrix; (ii) insulin-like growth factor 1 (IGF-1); (iii) fibroblast growth factor 2 (FGF-2); and (iv) at least one selected from the group consisting of a Wnt agonist, a bone morphogenetic protein (BMP) inhibitor, a transforming growth factor-β (TGF-β) inhibitor, and an epidermal growth factor (EGF).

Classes IPC  ?

• C12N 5/09 - Cellules tumorales
• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

[Problem] To provide a sheet or the like that has a less pronounced feeling of use when adhered to skin. [Solution] One aspect of the present invention provides a sheet having an adhesion surface that is used facing skin, said sheet including an elastomer and a light scattering material.

Classes IPC  ?

• C08L 21/00 - Compositions contenant des caoutchoucs non spécifiés
• A61B 5/25 - Électrodes bioélectriques à cet effet
• B32B 27/00 - Produits stratifiés composés essentiellement de résine synthétique
• B32B 27/18 - Produits stratifiés composés essentiellement de résine synthétique caractérisée par l'emploi d'additifs particuliers
• C08K 3/01 - Emploi de substances inorganiques en tant qu'adjuvants caractérisées par leur fonction
• C08K 3/22 - OxydesHydroxydes de métaux

Abrégé

A method of manufacturing an intravascular indwelling device uses a cylindrical holder (1) holding the intravascular indwelling device (20) in an internal space, and an outer cylinder (2) having an inner diameter larger than an outer diameter of the holder (1). The holder (1) holding the intravascular indwelling device (20) is accommodated in the outer cylinder (2), and a suspension(S) of cells of interest are supplied into the outer cylinder (2). The cells of interest are cultured by operating the outer cylinder (2) and the holder (1) such that the suspension(S) flows to the intravascular indwelling device (20) while being in contact with the intravascular indwelling device (20).

Classes IPC  ?

• A61L 31/16 - Matériaux biologiquement actifs, p. ex. substances thérapeutiques
• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains

Abrégé

An injection instrument set includes a tubular injection instrument in which an injection liquid is contained, and a guide member disposed on a surface of an injection target of the injection liquid. The injection instrument includes an injection needle which is inserted into the injection target to inject the injection liquid into the injection target. The guide member includes a guide passage which is disposed at a predetermined angle with respect to a surface of the guide member which comes into contact with the injection target and which allows the injection needle to be inserted and guides the injection needle onto the surface of the injection target, and an anti-slip portion disposed at a portion at which the guide member comes into contact with the surface of the injection target.

Classes IPC  ?

• A61M 5/32 - AiguillesParties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchonAccessoires pour introduire l'aiguille dans le corps ou l'y maintenirDispositifs pour la protection des aiguilles

Abrégé

The present invention provides: a composition and a food/beverage item which can promote the elongation of pili of an intestinal bacterium and exhibits an anti-bacterial activity; and a method for assisting the examination and diagnosis of a disease caused by a pathogenic bacterium or a pathogenic fungus. The present invention provides a composition containing a bacterium capable of producing 3-phenylpropionic acid (PPA) or 3-(4-hydroxyphenyl)propionic acid (4OHPPA). The present invention also provides a food/beverage item containing PPA or 4OHPPA. The present invention further provides a method for assisting the examination and diagnosis of a disease caused by a pathogenic bacterium or a pathogenic fungus. The method comprises: quantifying the amount of PPA or the amount of 4OHPPA in feces from a subject by using 2-nitrophenylhydrazine; and comparing a value obtained by the quantification of the amount of PPA or the amount of 4OHPPA with a reference value. When the value obtained by the quantification of the amount of PPA or the amount of 4OHPPA is smaller than the reference value, it is determined that the subject is possibly affected by the disease.

Classes IPC  ?

• A61K 35/74 - Bactéries
• A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
• A61K 35/741 - Probiotiques
• A61K 35/742 - Bactéries sporulées, p. ex. Bacillus coagulans, Bacillus subtilis, clostridium ou Lactobacillus sporogenes
• A61K 35/744 - Bactéries lactiques, p. ex. entérocoques, pédiocoques, lactocoques, streptocoques ou leuconostoques
• A61K 35/745 - Bifidobactéries
• A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
• A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
• A61P 1/02 - Préparations stomatologiques, p. ex. médicaments pour le traitement des caries, des aphtes, des périodontites
• A61P 7/00 - Médicaments pour le traitement des troubles du sang ou du fluide extracellulaire
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 13/02 - Médicaments pour le traitement des troubles du système urinaire de l'urine ou des voies urinaires, p. ex. acidificateurs d'urine
• A61P 15/02 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs pour les pathologies du vagin
• A61P 31/04 - Agents antibactériens
• A61P 31/10 - Antifongiques
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
• C12N 1/20 - BactériesLeurs milieux de culture
• C12N 9/02 - Oxydoréductases (1.), p. ex. luciférase
• C12N 9/88 - Lyases (4.)
• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

The present disclosure provides a method capable of more conveniently determining at an earlier stage whether a cell population collected from a vertebrate animal adipose tissue has mesenchymal stem cells (ASCs) at high purity, a kit for determining it, etc. The present disclosure includes, for example, a method for determining whether a cell population derived from an adipose tissue collected from a vertebrate animal comprises mesenchymal stem cells (ASCs) at high purity, the method comprising detecting expression of one or more genes in the cell population.

Classes IPC  ?

• C12Q 1/6876 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes

Abrégé

A cell population including macrophages that are CD11b positive, F4/80 positive, CD180 positive, and CD9 positive and that are derived from a tissue selected from the group consisting of placenta, umbilical cord, and amnion with a percentage of 75% or more, the cell population having cell viability of 80% or more.

Classes IPC  ?

• A61K 35/15 - Cellules de la lignée des myéloïdes, p. ex. granulocytes, basophiles, éosinophiles, neutrophiles, leucocytes, monocytes, macrophages ou mastocytesCellules précurseurs myéloïdesCellules présentatrices d’antigène, p. ex. cellules dendritiques
• A61K 8/98 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés d'origine animale
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
• A61Q 19/00 - Préparations pour les soins de la peau

Abrégé

The present invention provides T cells that express a recombinant receptor and satisfying conditions (I) and (II).　(I) T cells having reduced or eliminated expression and/or function of the PRDM1 gene (II) T cells having reduced or eliminated expression and/or function of the RCOR1 gene, and/or increased or activated expression of the c-Jun gene

Classes IPC  ?

• C12N 15/09 - Technologie d'ADN recombinant
• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
• A61P 35/00 - Agents anticancéreux
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• C12N 15/12 - Gènes codant pour des protéines animales
• C12N 15/13 - Immunoglobulines

Abrégé

A tactile feedback apparatus includes a pressable portion on which a pressing action is performed by a pressing portion, a detection unit that detects an external force acting on the pressable portion or detects a position of the pressing portion with respect to the pressable portion, a vibration actuator that applies vibration to the pressing portion, a storage unit that stores waveform information for driving the vibration actuator so as to provide the pressing portion with a specific tactile sensation, and a control unit that causes the vibration actuator to vibrate based on the waveform information at a specific point in time in the pressing action. The specific point in time is based on the external force or the position detected by the detection unit.

Classes IPC  ?

• G06F 3/01 - Dispositions d'entrée ou dispositions d'entrée et de sortie combinées pour l'interaction entre l'utilisateur et le calculateur

Abrégé

[Problem] To easily measure intestinal metabolites. [Solution] This quantification method for quantifying a substance contained in a biological specimen includes a step A for preparing a mixed specimen in which a prescribed amount of the aforementioned substance is mixed with a liquid containing an extract obtained by extracting two or more substances including the aforementioned substance from the specimen, a step B for drying and derivatizing the extract and the mixed specimen by the same method to obtain a derivatized substance group, and a step C for detecting the derivatized substance group obtained in step B by using a mass spectrometer.

Classes IPC  ?

• G01N 30/88 - Systèmes intégrés d'analyse, spécialement adaptés à cet effet, non couverts par un seul des groupes
• G01N 30/06 - Préparation

Abrégé

Provided is a method of producing a gene-modified T cell population, including mixing a cell population containing T cells with beads each having bound thereto a virus containing a target gene to introduce the target gene into each of the cells of the cell population, wherein the cell population containing the T cells is cultured in a solution containing a CD3 signal activator that is present without being immobilized on a solid phase.

Classes IPC  ?

• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
• C12N 15/86 - Vecteurs viraux

Abrégé

A method for manufacturing a collectively molded multi-optical transmission sheet assembly (100) provided with a collectively molded multi-optical transmission sheet (10) and an accommodation member (20), the method comprising: capturing an image of a position reference portion (25) provided in the accommodation member (20); generating a template image (I) that includes a reference position marker (I1) corresponding to the position reference portion (25) and a core position marker (I2) indicating the ideal position of each of core regions (11) with respect to the position reference portion (25) and that is superimposed such that the reference position marker (I1) and the captured image of the position reference portion (25) match; accommodating one end of the collectively molded multi-optical transmission sheet (10) in a disposition hole (23) of the accommodation member (20); capturing images of the core regions (11) exposed on an end surface at the one end accommodated in the disposition hole (23); adjusting the relative position of the collectively molded multi-optical transmission sheet (10) with respect to the accommodation member (20) such that the respective positions of the captured images of the core regions (11) and the respective positions of the core position markers (I2) corresponding to the respective positions match; and securing the collectively molded multi-optional transmission sheet (10) to the accommodation member (20).

Classes IPC  ?

• G02B 6/36 - Moyens de couplage mécaniques
• G02B 6/32 - Moyens de couplage optique ayant des moyens de focalisation par lentilles
• G02B 6/42 - Couplage de guides de lumière avec des éléments opto-électroniques

Abrégé

A method for manufacturing an integrally molded multi-light-transmission sheet assembly (100A) comprising an integrally molded multi-light-transmission sheet (10) and an accommodation member (20), wherein: a position reference section (25) and a reference structure (R) are imaged, the position reference section (25) being provided to the accommodation member (20), and the reference structure (R) including a reference position marker (R1) that corresponds to the position reference section (25) and core position markers (R2) that indicate individual ideal positions for core regions (11) with reference to the position reference section (25); an adjusted image is generated in which an image of the reference position marker (R1) and an image of the position reference section (25) are overlaid so as to coincide with each other; one end portion of the integrally molded multi-light-transmission sheet (10) is accommodated in a disposition hole (23) in the accommodation member (20); core regions (11) exposed on the end surface at the one end portion accommodated in the disposition hole (23) are imaged; the position of the integrally molded multi-light-transmission sheet (10) relative to the accommodation member (20) is adjusted such that the positions of images of the imaged core regions (11) and the positions of core position markers (R2) corresponding to the positions of the images coincide with each other; and the integrally molded multi-light-transmission sheet (10) is fixed to the accommodation member (20).

Classes IPC  ?

• G02B 6/36 - Moyens de couplage mécaniques
• G02B 6/32 - Moyens de couplage optique ayant des moyens de focalisation par lentilles
• G02B 6/42 - Couplage de guides de lumière avec des éléments opto-électroniques

Abrégé

An optical waveguide device includes a substrate, a first waveguide disposed on or in the substrate, and a second waveguide disposed on a first surface of the substrate, wherein the second waveguide includes a core and a cladding covering the core, wherein throughout an entirety of a predetermined region, a portion of the core overlaps the first waveguide when viewed from a direction normal to the first surface, in wherein the predetermined region, the core has a bottom surface in contact with the first surface and a convex surface connected to the bottom surface, and wherein the core includes a portion whose thickness gradually decreases from a widthwise center to widthwise ends in a transverse cross-sectional view.

Classes IPC  ?

• G02B 6/26 - Moyens de couplage optique
• G02B 6/02 - Fibres optiques avec revêtement

Abrégé

This cryotherapy device comprises a head part, a cooling mechanism, and a control unit. The head part has a probe that forms a working surface to be brought close to or into contact with the surface of a skin to be treated. The cooling mechanism cools the probe. The control unit controls the cooling mechanism such that the probe is maintained at a target temperature of 0°C or lower. The probe is configured so as to freeze the tissue of the skin through the working surface and thereby selectively induce the apoptosis of diseased cells including at least nevus cells.

Classes IPC  ?

• A61B 18/02 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci par refroidissement, p. ex. techniques cryogéniques

Abrégé

Provided is a method for acquiring data on the efficacy of a CDK4/6 inhibitor in lung cancer cells, the method comprising detecting an EGFR gene mutation and a CDKN2A/B gene deletion or loss-of-function mutation in lung cancer cells derived from a lung cancer patient. The presence of an EGFR gene mutation and a CDKN2A/B gene deletion or loss-of-function mutation indicates the efficacy of the CDK4/6 inhibitor.

Classes IPC  ?

• C12Q 1/6869 - Méthodes de séquençage
• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 35/00 - Agents anticancéreux
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

The present invention relates to a recovery assistance device, a recovery assistance system, and a storage medium. This recovery assistance device (22) comprises at least: an information acquisition unit (50) that acquires biological information relating to the physical function of a subject and treatment information including a plurality of treatment method candidates; a curve generation unit (52) that uses the acquired biological information and treatment information to generate, for each treatment method candidate, a prognosis prediction curve (94) indicating the prediction result of the degree of recovery of the physical function relative to elapsed time from a reference time point; and a display instruction unit 62 that instructs a display means (26) to compare and display the prognosis prediction curve (94) for each of the generated treatment method candidates.

Classes IPC  ?

• G16H 20/30 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies ou des activités physiques, p. ex. la physiothérapie, l’acupression ou les exercices

Abrégé

A bone conduction hearing-aid system includes an intracorporeal unit that is embedded under a scalp and that includes an intracorporeal vibration generator configured to generate vibration by receiving a magnetic field frequency, and an extracorporeal unit that is disposed extracorporeally, that is configured to generate the magnetic field frequency and to apply the magnetic field frequency to the intracorporeal unit, and that is configured to generate vibration by an extracorporeal vibration generator. The vibration generated by the intracorporeal unit and the vibration generated by the extracorporeal unit vibrate a skull.

Classes IPC  ?

• H04R 25/00 - Appareils pour sourds

Abrégé

A bone conduction hearing-aid unit embedded under a scalp. The bone conduction hearing-aid unit includes a vibration generator configured to generate vibration, and an anchor. A magnetic field frequency is applied to the vibration generator from the outside of the scalp to generate vibration. The vibration is transmitted to a skull via the anchor.

Classes IPC  ?

• H04R 25/00 - Appareils pour sourds

Abrégé

The purpose of the present invention is to provide: an agent that is for treating tendon disorders using platelets produced from an adipose tissue-derived mesenchymal stem cell line (ASCL), and that has a stable and excellent therapeutic effect on tendon disorders; and the like.　The present invention encompasses: an agent that is for treating tendon disorder, and that comprises, as an active ingredient, platelets produced by a production method having the following steps (A)-(C); and the like. (A) A step for inducing differentiation, into mature adipocytes, of at least one type of cells selected from stromal vascular cell groups including mesenchymal stem cells, adipocyte progenitor cells, and stromal cells in adipose tissues of a vertebrate; (B) a step for inducing dedifferentiation of the mature adipocytes obtained in step (A) to obtain an adipose tissue-derived mesenchymal stem cell line of the vertebrate; and (C) a step for culturing the adipose tissue-derived mesenchymal stem cell line obtained in step (B) in a culture liquid for inducing differentiation into megakaryocytic cells and that contains iron ions and iron transporters, and collecting platelets from a culture product.

Classes IPC  ?

• A61K 35/19 - PlaquettesMégacaryocytes
• A61P 19/00 - Médicaments pour le traitement des troubles du squelette
• A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
• C07K 14/62 - Insulines
• C07K 14/79 - Transferrines, p. ex. lactoferrines, ovotransferrines
• C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
• C12N 5/078 - Cellules du sang ou du système immunitaire
• C12N 5/0775 - Cellules souches mésenchymateusesCellules souches dérivées du tissu adipeux
• C12N 9/26 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2) agissant sur les liaisons alpha-glucosidiques-1, 4, p. ex. hyaluronidase, invertase, amylase
• C12N 9/50 - Protéinases
• C12N 9/66 - Élastase
• C12N 9/76 - TrypsineChymotrypsine

Abrégé

A bone conduction hearing-aid unit that is entirely embedded under a scalp. The bone conduction hearing-aid unit includes a vibration generating device configured to generate vibration, and an anchor fixed to a skull and configured to transmit the vibration to the skull. The vibration generating device is detachably fixed to the anchor.

Classes IPC  ?

• H04R 25/00 - Appareils pour sourds

Abrégé

Disclosed is a method for evaluating cell differentiation state, including inducing pluripotent stem cells to differentiate into mesodermal cells in a liquid medium by a first differentiation treatment for inducing pluripotent stem cells to differentiate into mesodermal cells and a second differentiation treatment for inducing the mesodermal cells to differentiate into cardiomyocytes; collecting a supernatant of the liquid medium comprising cells induced to differentiate by the second differentiation treatment; and measuring miRNA-3p in miR-1/133a cluster in the supernatant, where the miRNA-3p is at least one selected from a group consisting of miR-1-3p and miR-133a-3p, and the measured value of miRNA-3p is an index of differentiation into cardiomyocytes.

Classes IPC  ?

• C12Q 1/6881 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour le typage de tissu ou de cellule, p. ex. sondes d’antigène leucocytaire humain [HLA]
• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
• C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires

Abrégé

The present invention monitors whether an exercise prescription (for example, exercise amount, exercise intensity, and exercise frequency) presented by a doctor is being followed even outside of a hospital, and supports the exercise. A server 1 supports rehabilitation for a disease and comprises a patient information acquisition unit 51 and a patient information presentation unit 53. The patient information acquisition unit 51 acquires the value of a first index (the number of steps or the like) of exercise amount and the value of a second index (a heart rate or the like) of exercise intensity with respect to a predetermined exercise imposed on the patient as rehabilitation for the disease. The patient information presentation unit 53 presents, as support information for supporting rehabilitation for the disease, the number of steps for achieving a target heart rate of the patient including a combination of the acquired number of steps and heart rate (for example, the number of steps walked at a heart rate of 100 bpm or more).

Classes IPC  ?

• G16H 20/00 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients

Abrégé

The purpose of the present invention is to provide a novel therapeutic agent or prophylactic agent for dry eye, a therapeutic agent or prophylactic agent for a graft-versus-host disease, a corneal epithelial wound healing promoter, an inflammatory cell inhibitor that infiltrates the cornea, a tear fluid amount retaining agent, a corneal epithelial disorder inhibitor, a cell proliferation marker-positive cell inhibitor, and an inhibitor of lymphocyte differentiation into effector T cells. The present invention provides the following, each of which contains, as an active ingredient, a substance derived from a culture supernatant of stem cells: a therapeutic agent or prophylactic agent for dry eye; a therapeutic agent or prophylactic agent for a graft-versus-host disease; a corneal epithelial wound healing promoter; an inflammatory cell inhibitor infiltrating into the cornea; a tear fluid amount retaining agent; a corneal epithelial disorder inhibitor; a cell proliferation marker-positive cell inhibitor; or an inhibitor of lymphocyte differentiation into effector T cells.

Classes IPC  ?

• A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
• A61K 35/32 - OsOstéocytesOstéoblastesTendonsTénocytesDentsOdontoblastesCartilageChondrocytesMembrane synoviale
• A61P 27/04 - Larmes artificiellesSolutions d'irrigation
• A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe

Abrégé

Provided are a phthalocyanine dye represented by formula (1) and a method for producing the same. (In the formula, M, L, Q, R2, R3, R7, R8, R4, R5, R6, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, X2, and X3 are as defined in the claims.)

Classes IPC  ?

• C09B 47/04 - Phtalocyanines
• A61K 31/409 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil ayant quatre de ces cycles, p. ex. dérivés de la porphine, bilirubine, biliverdine
• A61K 31/695 - Composés du silicium
• A61K 47/56 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique
• A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
• A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
• A61P 35/00 - Agents anticancéreux
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes

Abrégé

A spintronics device is a spintronics device that generates a spin current, the device including: a metal layer; a semiconductor layer having a lower carrier mobility or a lower electrical conductivity than the metal layer; and a gradient layer located at a boundary between the metal layer and the semiconductor layer, and having a gradient in the carrier mobility or the electrical conductivity.

Classes IPC  ?

• H10N 50/85 - Matériaux de la région active
• H01F 10/32 - Multicouches couplées par échange de spin, p. ex. superréseaux à structure nanométrique
• H10B 61/00 - Dispositifs de mémoire magnétique, p. ex. dispositifs RAM magnéto-résistifs [MRAM]
• H10N 50/01 - Fabrication ou traitement
• H10N 50/10 - Dispositifs magnéto-résistifs

Abrégé

An object of the present invention is to provide further assistance in addition to assistance by tactile force transmission. An information presentation system includes a master device to which an operation by an operator is input and a slave device that operates in accordance with the operation input to the master device. Furthermore, the information presentation system includes a tactile force transmission unit, a calculation unit, and a presentation unit. The tactile force transmission unit controls tactile force transmission in the master device and the slave device. The calculation unit calculates physical characteristics of a substance in contact with the slave device on the basis of an external force input from the environment to the slave device while the slave device maintains a predetermined motion state. The presentation unit presents the physical characteristics of the substance calculated by the calculation unit.

Classes IPC  ?

• B25J 3/00 - Manipulateurs de type à commande asservie, c.-à-d. manipulateurs dans lesquels l'unité de commande et l'unité commandée exécutent des mouvements correspondants dans l'espace
• G06F 3/01 - Dispositions d'entrée ou dispositions d'entrée et de sortie combinées pour l'interaction entre l'utilisateur et le calculateur

Abrégé

An information processing device (10) according to an embodiment includes a determination unit (102) that generates a determination result in which the mental state of a subject is determined by inputting pulsation information relating to the heartbeat of the subject and body motion information relating to body motion of the subject to a trained model. The trained model has been trained using, for a plurality of providers that provide training data, pulsation information relating to heartbeat of the providers, body motion information relating to body motion of the providers, and index information relating to specific mental tendencies of the providers.

Classes IPC  ?

• A61B 5/16 - Dispositifs pour la psychotechnieTest des temps de réaction
• A61B 5/11 - Mesure du mouvement du corps entier ou de parties de celui-ci, p. ex. tremblement de la tête ou des mains ou mobilité d'un membre
• A61B 5/33 - Modalités électriques se rapportant au cœur, p. ex. électrocardiographie [ECG] spécialement adaptées à l’utilisation conjointe avec d’autres dispositifs
• A61B 5/332 - Dispositifs portables spécialement adaptés à cet effet
• A61B 5/352 - Détection des crêtes de l'onde R, p. ex. pour la synchronisation d'appareils de diagnosticEstimation de l’intervalle entre crêtes R
• A61B 10/00 - Instruments pour le prélèvement d'échantillons corporels à des fins de diagnostic Autres procédés ou instruments pour le diagnostic, p. ex. pour le diagnostic de vaccination ou la détermination du sexe ou de la période d'ovulationInstruments pour gratter la gorge

Abrégé

[Problem] To more appropriately support diagnosis when diagnosis accompanied by a medical action from a remote place is performed. [Solution] A remote medical support system 1 comprises a work mechanism 25, an operation mechanism 15, an operation control unit 313, and a presentation unit 314. The work mechanism 25 is a mechanism for performing a medical action including palpation of a subject. The operation mechanism 15 is a mechanism for receiving a remote operation for the work mechanism 25 from an operator. The operation control unit 313 controls the operation of the work mechanism 25 according to the remote operation received by the operation mechanism 15, and transmits the reaction force applied to the work mechanism 25 in response to the contact of the work mechanism 25 with the subject to the operator via the operation mechanism 15 as a tactile force. The presentation unit 314 presents, to the operator, support information for supporting diagnosis based on the medical practice acquired on the work mechanism side.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• B25J 3/00 - Manipulateurs de type à commande asservie, c.-à-d. manipulateurs dans lesquels l'unité de commande et l'unité commandée exécutent des mouvements correspondants dans l'espace

Abrégé

An optical coupling circuit device includes an optical circuit board including an optical circuit; an optical fiber coupled to the board; and an optical coupling waveguide formed in the board and configured to optically couple the fiber and the optical circuit. The fiber includes a cut surface obliquely cut at 3° to 30° to an optical axis of the fiber, and is coupled to the board at the cut surface. With a direction normal to the board being z-direction, a plane orthogonal to z-direction being xy-plane, a direction in which an optical axis of the optical coupling waveguide extends toward the fiber in xy-plane being x-direction, and a direction orthogonal to x-direction and z-direction being y-direction, second position of a leading end of a core end surface exposed at the cut surface is offset from first position of a coupling end of the optical coupling waveguide in x-direction and z-direction.

Classes IPC  ?

• G02B 6/30 - Moyens de couplage optique pour usage entre fibre et dispositif à couche mince

Abrégé

The present invention comprises a depression symptom determination unit 13 for determining a depression symptom of a subject, who is subject to determination, by inputting a feature vector generated on the basis of a feature amount of a conversation carried out by the subject to a machine-learned determination model, the determination being performed by the determination model, which is generated by machine learning using, as training data, conversation data for subjects satisfying prescribed extraction conditions and exclusion conditions relating to depression symptoms. By using, as an exclusion condition, a condition that subjects diagnosed with manic depression and subjects for whom a prescribed manic depression evaluation scale score is equal to or greater than a manic depression threshold value are excluded, it becomes possible to perform machine learning of the determination model without being affected by conversation data for when a manic depression patient is temporarily in a depressed state or a manic state, and it becomes possible to determine a depression symptom of the subject in a state of having the depression symptom as a personal characteristic of the subject instead of as a temporary state.

Classes IPC  ?

• A61B 10/00 - Instruments pour le prélèvement d'échantillons corporels à des fins de diagnostic Autres procédés ou instruments pour le diagnostic, p. ex. pour le diagnostic de vaccination ou la détermination du sexe ou de la période d'ovulationInstruments pour gratter la gorge

Abrégé

The present invention is provided with a depression symptom determination unit 13 for determining a depression symptom of a subject who is the subject of determination by inputting a feature vector generated on the basis of a feature amount of an interview with the subject into a machine-learned determination model. The determination is performed by the determination model generated by machine learning using, as learning data, interview data from subjects satisfying a predetermined extraction condition and exclusion condition regarding depression symptoms. The extraction condition is set on the basis of the result of a doctor diagnosis, while positive example/negative example labels are assigned to the learning data on the basis of the HAMD scores. Thus, it becomes possible, even for a subject who is temporarily in a state different from the result of a doctor diagnosis of a depression symptom, to determine a depression symptom according to the state of the subject during the interview.

Classes IPC  ?

• A61B 10/00 - Instruments pour le prélèvement d'échantillons corporels à des fins de diagnostic Autres procédés ou instruments pour le diagnostic, p. ex. pour le diagnostic de vaccination ou la détermination du sexe ou de la période d'ovulationInstruments pour gratter la gorge

Abrégé

An object of the present invention is to make control for friction compensation executed in a master-slave system more appropriate. A control system includes a master device, a slave device, and a control device. Furthermore, the control device includes a friction compensation control unit and a tactile force transmission unit. The friction compensation control unit calculates a force for assisting an operation in the master device with respect to friction generated in the slave device on the basis of a moving average of velocity of a movable portion in the slave device. The tactile force transmission unit assists the operation in the master device with a force calculated by the friction compensation control unit and controls tactile force transmission in the master device and the slave device.

Classes IPC  ?

• A61M 25/01 - Introduction, guidage, avance, mise en place ou maintien en position des cathéters
• A61B 18/14 - Sondes ou électrodes à cet effet
• A61B 34/37 - Robots meneurs-suiveurs
• B25J 9/16 - Commandes à programme
• B25J 13/02 - Moyens de commande à préhension manuelle
• G05B 15/02 - Systèmes commandés par un calculateur électriques
• A61B 18/00 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci
• A61B 34/30 - Robots chirurgicaux

Abrégé

This learning device, which performs machine learning, includes: an acquiring unit that acquires teacher data including input data and correct answer data, the input data including an input image including a reference object and input text that relatively specifies a target position by referring to the reference object; a generating unit that inputs the input data into a model to generate output data for specifying the target position, a reference position that is the position of the reference object, and a positional relationship of the target position with respect to the reference position; and an updating unit that updates a parameter of the model such that a loss obtained by inputting the output data and the correct answer data into a loss function decreases. The loss function is based on at least two of: a first error between the target position specified by the output data and the target position specified by the correct answer data; a second error between the reference position specified by the output data and the reference position specified by the correct answer data; and a third error between the positional relation specified by the output data and the positional relation specified by the correct answer data.

Classes IPC  ?

• G06N 20/00 - Apprentissage automatique
• G06N 3/04 - Architecture, p. ex. topologie d'interconnexion
• G06N 3/09 - Apprentissage supervisé

Abrégé

A learning apparatus for performing machine learning includes an acquisition unit configured to acquire teaching data including input data and correct answer data, the input data including an input image that contains a reference object and an input text that relatively designates a target position by referring to the reference object; a generation unit configured to input the input data to a model to generate output data for specifying the target position, a reference position that is a position of the reference object, and a positional relationship of the target position with respect to the reference position; and an update unit configured to update a parameter of the model to reduce a loss obtained by inputting the output data and the correct answer data to a loss function. The loss function is based on at least two errors of a first error between the target position specified by the output data and the target position specified by the correct answer data, a second error between the reference position specified by the output data and the reference position specified by the correct answer data, and a third error between the positional relationship specified by the output data and the positional relationship specified by the correct answer data.

Classes IPC  ?

• G06V 20/58 - Reconnaissance d’objets en mouvement ou d’obstacles, p. ex. véhicules ou piétonsReconnaissance des objets de la circulation, p. ex. signalisation routière, feux de signalisation ou routes
• G06V 10/80 - Fusion, c.-à-d. combinaison des données de diverses sources au niveau du capteur, du prétraitement, de l’extraction des caractéristiques ou de la classification

Abrégé

A feature amount extractor extracts a feature amount representing the feature of a brain wave from the brain wave of a subject, the brain wave being measured when a magnetic stimulation is applied to the brain of the subject. A mental disorder determiner determines whether or not the subject has a predetermined mental disorder on the basis of a feature amount variation that is a differential value between a feature amount extracted from a brain wave measured immediately before the magnetic stimulation and a feature amount extracted from a brain wave measured immediately after the magnetic stimulation.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 5/256 - Électrodes portables, p. ex. avec des sangles ou des bandes
• A61B 5/273 - Connexion des cordons, des câbles ou des fils conducteurs aux électrodes
• A61B 5/291 - Électrodes bioélectriques à cet effet spécialement adaptées à des utilisations particulières pour l’électroencéphalographie [EEG]
• A61B 5/374 - Détection de la répartition de fréquence dans les signaux, p. ex. détection des ondes delta, thêta, alpha, bêta ou gamma
• A61B 5/384 - Appareils d’enregistrement ou d’affichage spécialement adaptés à cet effet
• A61B 5/386 - Accessoires ou instruments supplémentaires à cet effet

Abrégé

An object of the present invention is to provide, for example, a therapeutic agent using a specific mesenchymal stem cell line derived from an adipose tissue (ASCL), the therapeutic agent (i) stably having an excellent therapeutic effect on one or more diseases selected from knee osteoarthritis, traumatic cartilage defect, and osteochondritis dissecans, (ii) loading less physical burden on a patient, (iii) requiring no restriction on patient's hospital visit management, and (iv) having no restriction on the number of treatments. A feature of the present invention is to use a mesenchymal stem cell line derived from an adipose tissue, the mesenchymal stem cell line being produced by a production method comprising: (A) inducing differentiation of one or more cells selected from a stromal vascular fraction of a vertebrate animal adipose tissue comprising a mesenchymal stem cell, an adipose progenitor cell, and a stromal cell into a mature adipocyte; and (B) inducing dedifferentiation of the mature adipocyte obtained in step (A) to obtain a mesenchymal cell line derived from the vertebrate animal adipose tissue.

Classes IPC  ?

• A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
• A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
• C12N 5/0775 - Cellules souches mésenchymateusesCellules souches dérivées du tissu adipeux

Abrégé

A composition for decomposition of trypsin or TMPRSS2 containing, as an active ingredient, bacteria that have 00502 protein, or a protein having 30% or higher sequence identity with an amino acid sequence of the 00502 protein and having a trypsin-binding ability; or bacteria that have 00509 protein, or a protein having 30% or higher sequence identity with an amino acid sequence of the 00509 protein and having a trypsin-binding ability.

Classes IPC  ?

• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
• A61P 31/04 - Agents antibactériens
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

One aspect of the present disclosure relates to a conversion device including an acquisition unit configured to acquire a first bit string having a first bit length L1; a conversion unit configured to convert, in accordance with conversion information that associates respective bit strings each having the first bit length L1 with bit strings each having a second bit length L2 uniquely assigned to the respective bit strings, the first bit string into a second bit string having the second bit length L2. The conversion information is created by searching for a clique that includes 2L1 or more nodes, from a graph including nodes and an edge representing the bit strings each having the second bit length L2 that satisfy a predetermined constraint condition.

Classes IPC  ?

• H03M 7/40 - Conversion en, ou à partir de codes de longueur variable, p. ex. code Shannon-Fano, code Huffman, code Morse
• H03M 7/46 - Conversion en, ou à partir de codes à longueur de série, c.-à-d. par représentation du nombre de chiffres successifs ou groupes de chiffres de même type à l'aide d'un mot-code et d'un chiffre représentant ce type

Abrégé

Provided is a cardiomyocyte group comprising cardiomyocytes differentiated from human pluripotent stem cells, the cardiomyocyte group having the following features (1), (2) and (3): (1) comprising myocardial troponin T-positive cells at 90% or more; (2) having spontaneous pulsation of 0-60 times/min; and (3) being within 30 days after differentiation has started. Also provided is a pharmaceutical composition comprising: said cardiomyocyte group and/or a myocardial sphere in which said cardiomyocyte group has been spheroidized; and a pharmaceutically acceptable carrier. Further provided is a method for producing a cardiomyocyte group, the method comprising: (a) a step for performing expansion culture of human pluripotent stem cells; (b) a step for culturing the human pluripotent stem cells resulting from the expansion culture, under a condition that allows the cells to differentiate into cardiomyocytes to produce a cell group containing 60% or more of cardiomyocytes; and (c) a step for removing human pluripotent stem cells and non-cardiomyocytes from the cell group.

Classes IPC  ?

• C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
• A61K 35/34 - MusclesCellules musculaires lissesCœurCellules souches cardiaquesMyoblastesMyocytesCardiomyocytes
• A61P 9/04 - Agents inotropes, c.-à-d. stimulants de la contraction cardiaqueMédicaments pour le traitement de l'insuffisance cardiaque
• C12N 5/0789 - Cellules souchesCellules progénitrices multipotentes
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus

Abrégé

[Problem] To more appropriately grasp the situation of a treatment in a medical procedure. [Solution] This medical device 1 comprises a slave-side actuator 212, an operation control unit 311, a state specification unit 313, and a situation determination unit 314. The slave-side actuator 212 causes a treatment mechanism 60 to perform a treatment on a patient. The operation control unit 311 calculates a control parameter relating to a force-tactile sensation on the basis of information relating to a position detected in the course of the treatment and controls the operation of the slave-side actuator 212 on the basis of the control parameter. The state specification unit 313 calculates a state parameter indicating the state of a treatment target site 40 with which the treatment mechanism 60 is in contact on the basis of the information relating to the position detected in the course of the treatment. The situation determination unit 314 performs a determination based on the control parameter and the state parameter, and thereby detects when the treatment by the treatment mechanism 60 has reached a prescribed situation.

Classes IPC  ?

• A61B 17/16 - Instruments pour réaliser une ostéoclasieForets ou ciseaux pour osTrépans

Abrégé

Provided is a primer set for the detection of a carbapenemase-producing Enterobacteriaceae bacterium, the primer set comprising: at least one LAMP primer set that is specific to each of carbapenemase genes, i.e., bla NDM type, bla OXA-type, bla IMP type, bla KPC type and bla VIM type, among various bacterial types of carbapenemase-producing Enterobacteriaceae bacteria; or at least one LAMP DNA chromatography primer set.

Classes IPC  ?

• C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
• C12Q 1/6844 - Réactions d’amplification d’acides nucléiques
• C12N 15/31 - Gènes codant pour des protéines microbiennes, p. ex. entérotoxines

Abrégé

An object of the present invention is to provide an anti-human norovirus agent which can inhibit infection with and proliferation of human norovirus. The present inventors have found that the object can be attained through provision of an anti-human norovirus agent comprising a fucose analog having an inhibitory action on glycosylation by fucosyltransferase (FUT) as an active ingredient. Examples of the active ingredient include a fucose analog represented by formula (III) or (IV) or a salt thereof: An object of the present invention is to provide an anti-human norovirus agent which can inhibit infection with and proliferation of human norovirus. The present inventors have found that the object can be attained through provision of an anti-human norovirus agent comprising a fucose analog having an inhibitory action on glycosylation by fucosyltransferase (FUT) as an active ingredient. Examples of the active ingredient include a fucose analog represented by formula (III) or (IV) or a salt thereof: An object of the present invention is to provide an anti-human norovirus agent which can inhibit infection with and proliferation of human norovirus. The present inventors have found that the object can be attained through provision of an anti-human norovirus agent comprising a fucose analog having an inhibitory action on glycosylation by fucosyltransferase (FUT) as an active ingredient. Examples of the active ingredient include a fucose analog represented by formula (III) or (IV) or a salt thereof: [In the formulas, each of formula (III) and formula (IV) represents an α-anomer or a β-anomer; each of R1, R3, and R4 is —OH or —OAc; R2 is a halogen atom, —OH, or —OAc; and R5 is —CH3, —C≡CH, —C≡CCH3, or —CH2C≡CH.]

Classes IPC  ?

• A61K 31/7024 - Esters de saccharides
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

This nanocarbon light source element is provided with: a nanocarbon light source disposed on a substrate; and a wavelength selection structure that is provided to the nanocarbon light source and that selects a specific wavelength. Light of the specific wavelength is emitted through the wavelength selection structure. A multi-wavelength nanocarbon light source array according to the present invention is provided with: nanocarbon light sources disposed in an array pattern on a substrate; and wavelength selection structures that are respectively provided to the plurality of nanocarbon light sources and that select different wavelengths. Light of the plurality of wavelengths is emitted through the wavelength selection structures.

Classes IPC  ?

• H01K 1/06 - Corps en carbone
• G01N 21/01 - Dispositions ou appareils pour faciliter la recherche optique
• G01N 21/3577 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge pour l'analyse de liquides, p. ex. l'eau polluée

Abrégé

This sugar intake/metabolism/reward inhibiting agent having lactic acid bacteria as an active ingredient is useful for controlling sugar palatability.

Classes IPC  ?

• A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
• A61K 35/744 - Bactéries lactiques, p. ex. entérocoques, pédiocoques, lactocoques, streptocoques ou leuconostoques

Abrégé

This thermal detector includes a recess provided on a substrate, a nanocarbon material layer cross-linked to the recess, a temperature-dependent resistance change material layer supported by the nanocarbon material layer, and a pair of electrodes connected to at least one of the resistance change material layer and the nanocarbon material layer.

Classes IPC  ?

• G01J 1/02 - Photométrie, p. ex. posemètres photographiques Parties constitutives
• H01L 21/822 - Fabrication ou traitement de dispositifs consistant en une pluralité de composants à l'état solide ou de circuits intégrés formés dans ou sur un substrat commun avec une division ultérieure du substrat en plusieurs dispositifs individuels pour produire des dispositifs, p.ex. des circuits intégrés, consistant chacun en une pluralité de composants le substrat étant un semi-conducteur, en utilisant une technologie au silicium
• H01L 27/04 - Dispositifs consistant en une pluralité de composants semi-conducteurs ou d'autres composants à l'état solide formés dans ou sur un substrat commun comprenant des éléments de circuit passif intégrés avec au moins une barrière de potentiel ou une barrière de surface le substrat étant un corps semi-conducteur
• H10N 15/00 - Dispositifs thermoélectriques sans jonction de matériaux différentsDispositifs thermomagnétiques, p. ex. utilisant l'effet Nernst-Ettingshausen

Abrégé

In the present invention, an infrared spectroscopy chip comprises: a first substrate; a second substrate that faces the first substrate; a flow path that is provided between the first substrate and the second substrate; and one or more nanocarbon light sources that are thermally insulated from the flow path and that irradiate the flow path with infrared light.

Classes IPC  ?

• G01N 21/01 - Dispositions ou appareils pour faciliter la recherche optique
• A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
• G01J 3/10 - Aménagements de sources lumineuses spécialement adaptées à la spectrométrie ou à la colorimétrie
• G01N 21/3577 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge pour l'analyse de liquides, p. ex. l'eau polluée
• H01K 1/06 - Corps en carbone

Abrégé

A therapeutic agent for small cell lung cancer containing an insulin-like growth factor 1 receptor (IGF1R) inhibitor as an active ingredient, and a method for determining whether or not an administration of the therapeutic agent for small cell lung cancer patients is effective, including: detecting the expression of YAP1 or its downstream factors in the cancer cells from the small cell lung cancer patient; and when the expression level of YAP1 or the expression level of the downstream factor of YAP1 is significantly higher than that of a control, it indicates an administration of the therapeutic agent is effective in treating the patient.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• C12N 5/09 - Cellules tumorales

Abrégé

In related-art methods of differentiating pluripotent stem cells into a desired cell type, there has not been established a differentiation induction method using human ES/iPS cells and being highly efficient. Many attempts have been made, including a stepwise differentiation induction method based on the control of culture conditions or the addition of, for example, various cell growth factors/differentiation factors to a culture solution, but the use of complicated culture steps is a big problem. A method of inducing differentiation into a desired cell type within a short period of time and with high efficiency by use of a pluripotent stem cell that actively undergoes cell differentiation, which is obtained by reducing an undifferentiated state of the pluripotent stem cell, has been developed, and thus the present invention has been completed.

Classes IPC  ?

• C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• C12N 5/0793 - Neurones
• C12N 15/09 - Technologie d'ADN recombinant
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens

Abrégé

An information processing apparatus in embodiments performs at least one trained machine learning model that includes an encoder and a decoder. The encoder receives inputs of text information including designation of a place, a first image that is an image captured by an image capturing apparatus and that includes the place, and a second image obtained by dividing a region for every identical object in the first image, and outputs tri-modal features that have been generated to include visual features of the first image that has been captured, visual features of the second image obtained by dividing the region, and language features of the text information. The decoder outputs a region on the first image corresponding to the designation of the place in the text information, by using the tri-modal features.

Classes IPC  ?

• G06V 10/80 - Fusion, c.-à-d. combinaison des données de diverses sources au niveau du capteur, du prétraitement, de l’extraction des caractéristiques ou de la classification
• G06T 7/11 - Découpage basé sur les zones
• G06V 10/764 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant la classification, p. ex. des objets vidéo
• G06V 10/77 - Traitement des caractéristiques d’images ou de vidéos dans les espaces de caractéristiquesDispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant l’intégration et la réduction de données, p. ex. analyse en composantes principales [PCA] ou analyse en composantes indépendantes [ ICA] ou cartes auto-organisatrices [SOM]Séparation aveugle de source
• G06V 10/774 - Génération d'ensembles de motifs de formationTraitement des caractéristiques d’images ou de vidéos dans les espaces de caractéristiquesDispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant l’intégration et la réduction de données, p. ex. analyse en composantes principales [PCA] ou analyse en composantes indépendantes [ ICA] ou cartes auto-organisatrices [SOM]Séparation aveugle de source méthodes de Bootstrap, p. ex. "bagging” ou “boosting”
• G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
• G06V 10/94 - Architectures logicielles ou matérielles spécialement adaptées à la compréhension d’images ou de vidéos
• G06V 20/70 - Étiquetage du contenu de scène, p. ex. en tirant des représentations syntaxiques ou sémantiques
• G10L 15/02 - Extraction de caractéristiques pour la reconnaissance de la paroleSélection d'unités de reconnaissance
• G10L 15/16 - Classement ou recherche de la parole utilisant des réseaux neuronaux artificiels
• G10L 15/22 - Procédures utilisées pendant le processus de reconnaissance de la parole, p. ex. dialogue homme-machine

Abrégé

This optical amplifier comprises a substrate, a first optical waveguide that is formed on the substrate, a semiconductor carbon nanotube layer that covers a prescribed region of the first optical waveguide, and an excitation configuration that excites the semiconductor carbon nanotube layer. The optical amplifier amplifies signal light by using an excitation state of electrons of the semiconductor carbon nanotube layer and stimulated emission resulting from incidence of the signal light on the prescribed region.

Classes IPC  ?

• H01S 3/10 - Commande de l'intensité, de la fréquence, de la phase, de la polarisation ou de la direction du rayonnement, p. ex. commutation, ouverture de porte, modulation ou démodulation
• G01J 1/02 - Photométrie, p. ex. posemètres photographiques Parties constitutives
• H01S 3/17 - Matériaux solides amorphes, p. ex. verre
• H01S 5/30 - Structure ou forme de la région activeMatériaux pour la région active
• H10N 15/00 - Dispositifs thermoélectriques sans jonction de matériaux différentsDispositifs thermomagnétiques, p. ex. utilisant l'effet Nernst-Ettingshausen

Abrégé

According to the embodiments, an information processing device comprises one or more processors that execute one or more trained machine learning models. The one or more trained machine learning models include an encoder and a decoder. The encoder receives text information that includes a designation of a place, a first image that has been captured by an imaging device and includes the place, and a second image that is segmented into regions by identical object in the first image as input and outputs trimodal features that have been generated to include image features of the captured first image, image features of the second image that is segmented into regions, and language features of the text information. The decoder uses the trimodal features to output a region of the first image that corresponds to the designation of the place in the text information.

Classes IPC  ?

• G06N 3/0455 - Réseaux auto-encodeursRéseaux encodeurs-décodeurs

Abrégé

According to the present invention, intracerebral amyloid-β lesions are detected noninvasively and at low cost. An intracerebral amyloid-β lesion estimation device according to one embodiment of the present invention comprises an estimation model which outputs the presence or absence of an amyloid-β lesion in the brain when information pertaining to blood is input, and also comprises an information acquisition unit that acquires information pertaining to the blood of a subject, an estimation unit that inputs, to the estimation model, the acquired information pertaining to the blood of the subject, and estimates the presence or absence of an amyloid-β lesion in the brain of the subject, and an estimation result output unit that outputs information pertaining to the estimated presence or absence of an amyloid-β lesion in the brain of the subject.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The purpose of the present invention is to provide a detection device that can detect a nucleic acid without depending on the skill or the like of a user, a detection method that uses the detection device, and a heating device that heats the detection device.　This detection device (1) detects an amplified nucleic acid generated from a target nucleic acid included in a sample and has a sample placement member (22) at which the sample is placed, a test piece (29) used for detection of the amplified nucleic acid, amplification members (50, 51, 52, 53) to which is fixed a reagent used to generate the amplified nucleic acid from the target nucleic acid, and supply paths (19, 25, 26, 27, 28) that supply the amplified nucleic acid toward the test piece, the amplification members being provided at the supply paths.

Classes IPC  ?

• C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
• C12Q 1/04 - Détermination de la présence ou du type de micro-organismeEmploi de milieux sélectifs pour tester des antibiotiques ou des bactéricidesCompositions à cet effet contenant un indicateur chimique
• C12Q 1/6844 - Réactions d’amplification d’acides nucléiques

Abrégé

Provided are: a fluorine-containing amorphous carbon film which has characteristics of hard coating, antireflection, and antifouling; and a method for producing the same. This fluorine-containing amorphous carbon film is a monolayer film that is composed of carbon, fluorine, and oxygen. The average fluorine content in the film thickness direction is 30% by atom to 40% by atom inclusive, the average oxygen content in the film thickness direction is 5% by atom to 20% by atom inclusive, and the remainder is made up of carbon atoms. With respect to this fluorine-containing amorphous carbon film, a substrate is located in a chamber, and a starting material gas which is represented by a chemical formula that is composed only of carbon and fluorine, and an inert gas for diluting the starting material gas are introduced into the chamber, so that a fluorine-containing amorphous carbon film is formed on the substrate under plasma generation. The mixing ratio of the inert gas into the starting material gas is set to be larger than 1/4 but smaller than 11/1 in terms of the flow rate ratio into the chamber.

Classes IPC  ?

• G02B 1/14 - Revêtements protecteurs, p. ex. revêtements durs
• C03C 17/22 - Traitement de surface du verre, p. ex. du verre dévitrifié, autre que sous forme de fibres ou de filaments, par revêtement par d'autres matières inorganiques
• C23C 16/26 - Dépôt uniquement de carbone
• G02B 1/11 - Revêtements antiréfléchissants
• G02B 1/18 - Revêtements pour garder des surfaces optiques propres, p. ex. films hydrophobes ou photocatalytiques

Abrégé

The present invention addresses the problem of providing a method for identifying a candidate cancer patient for anti-PD-1 antibody therapy who exhibits responsiveness to a first anti-PD-1 antibody dose and demonstrates responsiveness to continuous administration of second and subsequent doses, and who experiences less of a burden therefrom.　The present invention is a method for identifying a candidate cancer patient X who is responsive to an anti-PD-1 antibody therapy, said method comprising a step 1 for measuring the mRNA expression level of FGFBP2 in a peripheral blood mononuclear cell of a cancer patient, and a step 2 for comparing the mRNA expression level of the FGFBP2 with a prescribed cut-off value, and being configured in a manner such that the prescribed cut-off value being exceeded by the mRNA expression level of the FGFBP2 demonstrates that the cancer patient is a candidate cancer patient X for administration of a first anti-PD-1 antibody dose.

Classes IPC  ?

• C12Q 1/6869 - Méthodes de séquençage
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C12N 15/12 - Gènes codant pour des protéines animales
• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

A control system includes a master device, a slave device, and a control device. Furthermore, the control device includes a tactile force transmission unit and a mode setting unit. The tactile force transmission unit controls tactile force transmission in the master device and the slave device. The mode setting unit changes an amplification factor of force transmitted from the slave device to the master device in a specific section in which a moving element of the slave device moves on the basis of a physical quantity in the moving element of the slave device.

Classes IPC  ?

• B25J 13/08 - Commandes pour manipulateurs au moyens de dispositifs sensibles, p. ex. à la vue ou au toucher
• A61B 34/37 - Robots meneurs-suiveurs

Abrégé

To provide a method and a device for producing formic acid.　Provided are a method and a device for producing formic acid by using a conductive diamond electrode and electrolytically reducing carbon dioxide in a single-chamber electrolytic cell.

Classes IPC  ?

• C25B 9/00 - Cellules ou assemblages de cellulesÉléments de structure des cellulesAssemblages d'éléments de structure, p. ex. assemblages d'électrode-diaphragmeCaractéristiques des cellules relatives aux procédés
• C25B 3/03 - Hydrocarbures acycliques ou cycliques
• C25B 3/26 - Réduction du dioxyde de carbone
• C25B 9/15 - Cellules à circulation de fluide
• C25B 11/02 - ÉlectrodesLeur fabrication non prévue ailleurs caractérisées par la configuration ou la forme

Abrégé

A method for producing a metabolically activated liver organoid, said method comprising a step for culturing primary hepatocytes or hepatocyte-like cells in a differentiation culture medium to obtain a metabolically activated liver organoid, wherein the differentiation culture medium contains: one or two types of agonist selected from the group consisting of growth hormone receptor agonists and prolactin receptor agonists; and a glucocorticoid receptor agonist.

Classes IPC  ?

• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• C12N 1/00 - Micro-organismes, p. ex. protozoairesCompositions les contenantProcédés de culture ou de conservation de micro-organismes, ou de compositions les contenantProcédés de préparation ou d'isolement d'une composition contenant un micro-organismeLeurs milieux de culture
• C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables

Abrégé

The present invention assists diagnosis of atrial septal defect. A program according to one embodiment of the present invention causes an estimation device to function as: an electrocardiogram acquisition unit that acquires an electrocardiogram of a patient; an electrical potential data acquisition unit for acquiring, from the electrocardiogram of the patient, time-series data of the electrical potential serving as the source of the electrocardiogram of the patient; an estimation unit for inputting the time-series data of the electrical potential serving as the source of the electrocardiogram of the patient into an estimation model for estimating, from time-series data of the electrical potential serving as the source of an electrocardiogram of a subject, the probability that the subject has atrial septal defect, and outputting the probability that the patient has atrial septal defect; and a display unit for displaying the probability that the patient has atrial septal defect.

Classes IPC  ?

• A61B 5/346 - Analyse des électrocardiogrammes

Abrégé

A magnetic detector (1) comprises: a diamond substrate (10) having an NV center (11); a transparent first substrate (13) on which the diamond substrate is disposed; a radiating body (24) provided on a surface of the first substrate (13) or on the surface of the diamond substrate (10) that is opposite from the surface on which the NV center (11) is provided; and a second substrate (15) which has an opening (16) and on which the first substrate (13) is disposed. The diamond substrate (10) is at least partially exposed through the opening (16).

Classes IPC  ?

• G01R 33/20 - Dispositions ou appareils pour la mesure des grandeurs magnétiques faisant intervenir la résonance magnétique
• G01N 24/00 - Recherche ou analyse des matériaux par l'utilisation de la résonance magnétique nucléaire, de la résonance paramagnétique électronique ou d'autres effets de spin